Paris - Mayer Brown advised AccelLAB, a Canadian CRO specialized in the pre-clinical assessment of new medical devices on it acquisition by CiToxLAB, a leading player among preclinical CROs.

AccelLAB was founded in 2004 by Dr. Guy Leclerc, an Interventional Cardiologist who headed the department of Cardiology and Cardiac Surgery of the Centre Hospitalier de l’Université de Montreal (CHUM). As an interventional cardiologist practitioner, Guy Leclerc has been a pioneer in applying what we call today translational research in the field of medical devices, helping client companies in the development of new cardiac stents, valves, pacemakers, etc. The services were more recently enlarged to other areas such as orthopedic, ENT (Ear, Nose and Throat) and dermatology specialties.

AccelLAB has a staff of around 100 people and the facilities include operating rooms, in particular for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.

Mayer Brown advised AccelLAB on the legal aspects with regard to French law, alongside the law firm McMillan who advised on the Canadian law aspects.

Mayer Brown team advising AccelLAB on this deal included: Arnaud Pérès (Partner) and Arnaud Mouton.